Proton Therapy Publication Proton Therapy Publication
Menu

Proton beam therapy reirradiation for breast cancer: Multi-institutional prospective PCG registry analysis.

July 2019
Executive summary

This study analyzed 50 patients received PBT reRT for breast cancer in the prospective Proton Collaborative Group (PCG) registry. Median reRT dose was 55.1 Gy and median cumulative dose was 110.6 Gy (70.6-156.8). ReRT included regional nodes in 84% (66% internal mammary node [IMN]).

Grade 3 AEs were experienced by 16% of patients (10% acute, 8% late). All grade 3 AEs occurred in patients receiving IMN reRT (P = 0.08). At 1 year, LRFS was 93%, and OS was 97%. This study concluded that PBT reRT is well tolerated with favorable local control. Toxicity was acceptable despite median cumulative dose > 110 Gy

Key content topics
Reirradiation
Top cancer treatments
Breast
Reirradiation

Related contents

Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.
en
Link to the fully detailed content
Proton Therapy Publication
June 2022
Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.
en
Link to the fully detailed content